Group 1 - The core business of the company is the research, production, and sales of superconducting MRI systems and specialized magnets in the high-tech field [1] - As of the latest quarterly report for Q3 2024, the company reported a revenue of 86.11 million yuan, a year-on-year decrease of 13.44%, and a net loss of approximately 15.88 million yuan, a year-on-year decline of 129.77% [1] - The company has a current market capitalization of 1.744 billion yuan and a price-to-book ratio of 6.39 [1] Group 2 - The company is recognized as a high-tech enterprise with a focus on independent research and development, having received several accolades including "Technology Small Giant Enterprise" and "National Specialized and New Small Giant Enterprise" [1] - The company has one institutional holder, which is a fund holding a total of 47,300 shares valued at 0.01 million yuan [1] - The average price-to-earnings (PE) ratio in the industry is significantly higher at 45.15 compared to the company's PE ratio of -30.08 [2]
辰光医疗收盘上涨1.40%，最新市净率6.39，总市值17.44亿元